Inositol for PCOS: Myo- vs D-Chiro- and the 40:1 Ratio Explained

Polycystic ovary syndrome (PCOS) affects roughly one in ten women of reproductive age and is fundamentally a syndrome of insulin signalling dysfunction overlapping with hyperandrogenism. Inositol — a sugar alcohol previously classified as a B vitamin — has become a first-line supplement in PCOS guidelines because two specific stereoisomers act as second messengers in the insulin pathway. The trial evidence is unusually strong for a supplement, but the form and ratio matter.

The two isomers and what they do

Myo-inositol (MI) is the most abundant inositol isomer in the body and the precursor of inositol triphosphate (IP3), which mediates intracellular calcium release. D-chiro-inositol (DCI) is produced by epimerisation of MI and primarily mediates glycogen synthesis and androgen biosynthesis. In healthy tissue, MI predominates in granulosa cells (where it supports follicle quality and oocyte maturation) while DCI predominates in liver and muscle (where it supports insulin sensitisation). The ratio in human plasma is roughly 40:1 MI to DCI [1].

The "ovarian paradox" and why pure DCI failed

Early PCOS trials used D-chiro-inositol alone, based on the observation that women with PCOS had lower DCI relative to MI in skeletal muscle. Those trials produced improvements in insulin sensitivity but unexpectedly worsened oocyte quality at higher DCI doses. The 2008 "ovarian paradox" paper showed that supplementing DCI alone depleted ovarian MI and harmed follicle development [2]. The field then shifted to combination therapy.

The 40:1 ratio trials

The 40:1 ratio (typically 2 g MI + 50 mg DCI, taken twice daily) has been the most-studied combination. A 2012 RCT in 50 women with PCOS undergoing IVF compared 4 g/day MI alone, 1 g/day DCI alone, and 4 g/day MI + 100 mg/day DCI; the combination showed superior oocyte quality and embryo development [3]. A 2017 systematic review of 12 trials concluded inositol — most commonly in the 40:1 ratio — improved menstrual regularity, ovulation, free testosterone, and insulin resistance [4].

Comparison with metformin

Several head-to-head trials have compared inositol to metformin. A 2017 meta-analysis of 6 RCTs (361 women) found inositol equivalent to metformin for restoring ovulation and improving insulin resistance over 6 months, with substantially fewer gastrointestinal side effects [5]. Metformin remains the prescription-grade insulin-sensitiser of choice for PCOS, but inositol is a reasonable alternative or adjunct for women who do not tolerate metformin.

What inositol does not do

Inositol does not address the hyperandrogenism caused by adrenal sources, does not replace combined oral contraceptives for menstrual control in women who do not want pregnancy, and does not consistently produce weight loss. Effects on free testosterone are real but modest (typically 10–20% reduction). Acne and hirsutism improvements lag behind menstrual regularity and may take 6 months to detect [4].

Dose, duration, and during pregnancy

The dose used in nearly every trial is 4 g/day of MI plus 100 mg/day of DCI, split into two doses, taken with food. Effects on cycle regularity appear at 3 months; effects on insulin resistance appear at 3–6 months. Inositol has been studied in pregnancy for prevention of gestational diabetes in women with PCOS or family history — three trials show reduced GDM incidence at 4 g/day MI [6]. It appears safe in pregnancy at these doses but should be cleared with the obstetric team.

Safety and interactions

Inositol is well tolerated. Mild gastrointestinal effects (loose stools, nausea) occur in 5–10% of users at 4 g/day and usually resolve in a week. There are no clinically significant drug interactions, though combination with metformin or insulin can require monitoring for hypoglycaemia in women who exercise heavily.

Practical takeaway

For adult women with confirmed PCOS, a 4 g + 100 mg myo/D-chiro combination at the 40:1 ratio is the form supported by the strongest trial evidence. Expect a 3-month trial before judging menstrual regularity and 6 months for hyperandrogenism endpoints. Inositol is one of the supplements with reasonable RCT support and a regulatory-grade product profile in Europe; it is not a substitute for the lifestyle and pharmacological backbone of PCOS management.